11–13 October 2023 Milan
![]() |
![]() |
![]() |
![]() |
1-P | Inclusion of optic neuritis improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis | Lilyana Amezcua | ![]() |
![]() |
|||
2-P | How Well Do Junior Neurology Residents Recognize Multiple Sclerosis? Analysis of the Close the Loop Resident Clinical Acumen Project | Claudia Zbrzeski | ![]() |
![]() |
|||
3-P | Clinical and radiological phenotype of adult-onset neurogenetic diseases mimicking multiple sclerosis: a multinational observational study | Gabrielle Macaron | ![]() |
![]() |
|||
18-P | Humoral signatures of MOG-antibody associated disease | Jan Lünemann | ![]() |
![]() |
|||
19-P | Predictors of the risk of relapse in children with MOGAD | Akash Virupakshaiah | ![]() |
![]() |
|||
21-P | Clinical predictors of outcomes in pediatric myelin oligodendrocyte glycoprotein antibody disease | Alexandra Kornbluh | ![]() |
![]() |
|||
23-P | Late-onset MOGAD : a French multicenter retrospective study | Julie Pique | ![]() |
![]() |
|||
40-P | Relationship between brain reserve and timing of clinical onset in Multiple Sclerosis | Maria Petracca | ![]() |
![]() |
|||
42-P | Patterns and Predictors of Conversion from Relapsing-Remitting to Secondary Progressive MS: A Longitudinal Study Using the Danish Multiple Sclerosis Registry | Melinda Magyari | ![]() |
![]() |
|||
43-P | Clinic-level quality of care affects patient outcomes in relapse-onset MS | Anna He | ![]() |
![]() |
|||
44-P | Racial differences in disability and treatment of relapsing MS in a universal healthcare context | Anna He | ![]() |
![]() |
|||
45-P | Disease modifying therapy use among people living with multiple sclerosis based on socioeconomic status and urban/rural residence: a retrospective cohort study from Alberta, Canada | Erin Balcom | ![]() |
![]() |
|||
47-P | Epidemiology of Relapsing Remitting Multiple Sclerosis in Chile between 2010 and 2021 | Lorna Galleguillos | ![]() |
![]() |
|||
54-P | Prognostic factors of Disease Activity in Newly-diagnosed Teriflunomide Treated Patients with Multiple Sclerosis - A Nationwide Danish Study | Mie Reith Mahler | ![]() |
![]() |
|||
58-P | Sex-related Differences in Treatment of Multiple Sclerosis - a retrospective analysis of the Austrian National MS registry | Harald Hegen | ![]() |
![]() |
|||
62-P | Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies: a monocentric retrospective study | Oussama Sahloul | ![]() |
![]() |
|||
71-P | Performance of gold-standard cognitive measures for detecting change over time: Longitudinal analysis of retrospective data | Victoria Leavitt | ![]() |
![]() |
|||
78-P | Linking fatigue trajectories in relapsing-remitting multiple sclerosis to incidence of psychiatric comorbidities and productivity loss in the years following initiation of disease modulating therapy | Simon Englund | ![]() |
![]() |
|||
80-P | The Next Generation Learning Health System for Multiple Sclerosis (NextGen MS): Study design, demographics, and analysis of system-level variation in baseline characteristics. | Falguni Mehta | ![]() |
![]() |
|||
87-P | Patient-reported factors impacting well-being in individuals with multiple sclerosis - a cross-sectional study | Sabrina Islamoska | ![]() |
![]() |
|||
92-P | Uveitis and central nervous system involvement: retrospective follow-up of a cohort of 175 uveitis patients | Alexandra Maury | ![]() |
![]() |
|||
93-P | Genotype-phenotype correlation in multiple sclerosis: a study of predictive genetic markers for autoimmune comorbidities with an innovavtive approach tolink genomic data with electronic administrative health databases | Nadia Barizzone | ![]() |
![]() |
|||
94-P | Elevated Incidence and Prevalence of Peripartum Mental Illness in Women with Multiple Sclerosis | Ruth Ann Marrie | ![]() |
![]() |
|||
98-P | The influence of comorbid depression and anxiety on cognition in people with multiple sclerosis | David Freedman | ![]() |
![]() |
|||
99-P | Prevalence and patterns of comorbidity in people with multiple sclerosis | Marie Lynning | ![]() |
![]() |
|||
109-P | PAK1 and E2F1 dysregulation induces a p21-mediated defect of oligodendrocyte differentiation in a cerebral organoid model of multiple sclerosis | Nicolas DAVIAUD | ![]() |
![]() |
|||
118-P | Meta-analysis for Neurofilament Light Chain (NfL) as Biomarker in Mouse Experimental Autoimmune Encephalomyelitis (EAE) Studies | Lakshmi Narendra Bodduluru | ![]() |
![]() |
|||
120-P | Investigation of cerebrospinal fluid antibody specificity in primary progressive MS | Jerry Lin | ![]() |
![]() |
|||
140-P | Age-associated change in Th17 and cytokine response in Multiple Sclerosis | Zongqi Xia | ![]() |
![]() |
|||
150-P | Cytomegalovirus in multiple sclerosis patients: how does it interact with the infection by Epstein-Barr virus and human herpesvirus 6A/B? | Roberto Alvarez-Lafuente | ![]() |
![]() |
|||
151-P | Environmental risk factors in multiple sclerosis. FRAMES study. | Roberto Álvarez-Lafuente | ![]() |
![]() |
|||
162-P | Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies | Victoria Findlen | ![]() |
![]() |
|||
176-P | Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity | Melissa Karr | ![]() |
![]() |
|||
177-P | Interpretable Thalamic Volume Charts in Multiple Sclerosis | Melissa Karr | ![]() |
![]() |
|||
179-P | Efficacy of Ofatumumab on Microglial Activity and Brain Iron in Patients With Relapsing Forms of Multiple Sclerosis: Results From a 9-Month Study | Venkateswarlu Bonala | ![]() |
![]() |
|||
180-P | Cortical glial activity is linked with serum GFAP levels and cortical atrophy in multiple sclerosis patients treated with high-efficacy DMTs: a F-18PBR06-PET study | Tarun Singhal | ![]() |
![]() |
|||
181-P | Brain Age and Quantitative Susceptibility Mapping of Chronic Active Lesions in Relapsing Multiple Sclerosis | Lars Skattebl | ![]() |
![]() |
|||
182-P | Paramagnetic rim lesions: a longitudinal evaluation with treatment associations | Christopher Hemond | ![]() |
![]() |
|||
189-P | Early cortical thinning of posterior and temporal regions in relapsing-remitting multiple sclerosis | Sarah Levy | ![]() |
![]() |
|||
192-P | Contribution of 7T brain MRI to the detection of cortical lesions at the earliest stage of multiple sclerosis. | Jean Pelletier | ![]() |
![]() |
|||
203-P | Depicting longitudinal MS disease course using lesion parenchymal fraction (LPF): a quantified expression of the topographical model of MS | Stephen Krieger | ![]() |
![]() |
|||
209-P | Spinal cord microstructural damage measured in recently diagnosed Relapsing Remitting MS patients : prognostic value at 5-year | Vivien Caron | ![]() |
![]() |
|||
214-P | OCT-based differentiation between MOGAD and MS after the first optic neuritis episode | Thivya Pakeerathan | ![]() |
![]() |
|||
219-P | Creation and performance of the International MOGAD Diagnostic Criteria | Brenda Banwell | ![]() |
![]() |
|||
221-P | Highly Sensitive Proteomic Immunoassays to Identify Novel Serum Biomarkers for Multiple Sclerosis Disease Progression in Natalizumab Treated Patients | Sjors In t Veld | ![]() |
![]() |
|||
227-P | Comparison of Baseline Demographic Specific Reference Ranges for NfL and GFAP Between Serum and Plasma in Healthy Controls | KAVITA NAIR | ![]() |
![]() |
|||
232-P | Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population | William Kilgo | ![]() |
![]() |
|||
235-P | Serum Biomarkers of Clinical and Radiographic Disease Progression in Multiple Sclerosis | Melissa Karr | ![]() |
![]() |
|||
237-P | Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis | Synne Brune-Ingebretsen | ![]() |
![]() |
|||
238-P | The Impact of Natalizumab Treatment on Cerebrospinal Fluid Oligoclonal Bands in Multiple Sclerosis Patients | Francois Jacques | ![]() |
![]() |
|||
239-P | Serum neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients | Antonio Bertolotto | ![]() |
![]() |
|||
252-P | Plasma lipidomic profiling by mass spectrometry for Multiple Sclerosis diagnosis and disease activity stratification (LipidMS) | Justus Lattau | ![]() |
![]() |
|||
253-P | Long-Term Immune Response to COVID-19 Vaccines in Multiple Sclerosis: A Multi-Center Study | Sarah Wesley | ![]() |
![]() |
|||
268-P | Ultra-high field MRI-derived brain age correlates with cognitive performance in people with multiple sclerosis | Francesco La Rosa | ![]() |
![]() |
|||
275-P | Phase 2 Efficacy and Safety of Frexalimab: 6-Month Results of a Novel CD40L Inhibitor in Relapsing Multiple Sclerosis | Patrick Vermersch | ![]() |
![]() |
|||
276-P | Phase III MIRANTIBUS trial: results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis. | Alexey Boyko | ![]() |
![]() |
|||
277-P | Durability of Immune Response to COVID-19 Vaccines in Persons with MS on B-cell Depleting Therapy | Rebecca Straus Farber | ![]() |
![]() |
|||
281-P | Treatment of six non-active secondary progressive MS patients with nasal anti-CD3 monoclonal antibody (Foralumab): safety, biomarker, and disability outcomes | Tanuja Chitnis | ![]() |
![]() |
|||
282-P | Phase I trial of faecal microbiota transplantation in MS | Bob van Oosten | ![]() |
![]() |
|||
286-P | Changes in Immunoglobulin in Patients with Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies | Brandi Vollmer | ![]() |
![]() |
|||
288-P | COVID-19 Outcomes and Seropositivity Rates Following SARS-CoV-2 Vaccine and/or Infection in Ofatumumab-treated RMS Patients: Data from the ALITHIOS Open-label Extension Study | Bhavesh Kshirsagar | ![]() |
![]() |
|||
295-P | VISIONARY-MS Topline Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis | Heidi Beadnall | ![]() |
![]() |
|||
296-P | harnessing the endogenous adaptive response to hypoxia-ischemia as a therapy for neurodegeneration in multiple sclerosis | Carlos Camara | ![]() |
![]() |
|||
309-P | DISCOntinuation of disease-modifying therapies in Multiple Sclerosis (DISCOMS): Primary results of the extension trial | John Corboy | ![]() |
![]() |
|||
314-P | Endogenous IgG4 Concentration Impacts Natalizumab Arm Exchange and Intact Drug Pharmacokinetics | Bradley Messmer | ![]() |
![]() |
|||
315-P | ACAPELLA: Hypogammaglobulinemia in Ocrelizumab-Treated Patients, Year Six Data | Joshua Katz | ![]() |
![]() |
|||
318-P | GA Depot (long-acting IM injection of glatiramer acetate) presents improved safety and tolerability features: results from a multi-national, double-blind, placebo-controlled phase III study in subjects with relapsing forms of Multiple Sclerosis. | Ehud Marom | ![]() |
![]() |
|||
320-P | Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy | Brit Ellen Rd | ![]() |
![]() |
|||
323-P | The role of ganglion cell inner plexiform layer thickness in evaluating the neuroprotective role of phenytoin in the visual pathway | Srikirti Kodali | ![]() |
![]() |
|||
325-P | Risk of cardiovascular disease in patients treated with fingolimod compared to natalizumab: A nationwide cohort study in Denmark | Elisabeth Framke | ![]() |
![]() |
|||
331-P | Stopping Fingolimod is associated with a high risk of radiological disease reactivation | Rolf Holm | ![]() |
![]() |
|||
338-P | The use of pragmatic randomized trials in Multiple Sclerosis: a systematic overview | perrine Janiaud | ![]() |
![]() |
|||
339-P | Patient preference and time allocation assosiated with transition from intravenous to subcutaneus administration of natalizumab in patients with relapsing remitting MS - a questionnaire study | Anna Almroth | ![]() |
![]() |
|||
345-P | Disparities in DMT Treatment Access: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies | Victoria Leavitt | ![]() |
![]() |
|||
350-P | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | Scott Newsome | ![]() |
![]() |
|||
359-P | Efficacy and safety of diroximel fumarate compared with interferon beta-1a in relapsing-remitting multiple sclerosis: Propensity Score Matching Analysis of Phase 3 Data from EVOLVE-MS-1 and DECIDE | Christin Henning | ![]() |
![]() |
|||
360-P | Incidence of new menstrual cycle disorders in a cohort of 120 women with multiple sclerosis treated with cladribine: a single-arm oberservational multi-center cohort study | Birte Elias-Hamp | ![]() |
![]() |
|||
374-P | Increased risk of cancer in multiple sclerosis: a birth cohort study in Wales using routinely collected data | Madeeha Khan | ![]() |
![]() |
|||
375-P | Similarities in Brain Damage Across the Spectrum of Multiple Sclerosis | Bhavesh Kshirsagar | ![]() |
![]() |
|||
379-P | Validation of the 2023 diagnostic criteria for MOGAD at a tertiary care center | Linda Nguyen | ![]() |
![]() |
|||
383-P | Is Fatigue in MS the same one manifesting as Wearing-off Symptom in Natalizumab treated patients? | Giuseppe Magro | ![]() |
![]() |
|||
395-P | Trait Conscientiousness and Multiple Sclerosis: Predicting Disease Progression and Assessing the Effects of an App-Supported Behavioral Intervention | Michael Jaworski | ![]() |
![]() |
|||
417-P | Comparison of Vision-Related Quality of Life in AQP4 NMOSD and MOGAD | Adnan A. Gassan | ![]() |
![]() |
|||
418-P | Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and MOG/AQP4 Testing Landscape in Canada | Jodie Burton | ![]() |
![]() |
|||
421-P | The Neutrophil-to-lymphocyte ratio is a marker of acute inflammation but does not predict relapses or disease severity in a UK cohort of people with MOGAD and NMOSD | Radu Tanasescu | ![]() |
![]() |
|||
423-P | Assessing the performance of cell based assays for MOGAD in the real world setting of a resource poor region - Impact of the international MOGAD diagnostic criteria | Lekha Pandit | ![]() |
![]() |
|||
424-P | Depression and Cognition in Multiple Sclerosis: Longitudinal Evidence of a Specific Link to Executive Control | Jordyn Anderson | ![]() |
![]() |
|||
435-P | Assessing likelihood of secondary progressive multiple sclerosis in Sweden and Denmark: A federated learning analysis unveiling modestly higher odds in Sweden | Lars Forsberg | ![]() |
![]() |
|||
443-P | The impact of changing diagnostic criteria on disability in a 25-year Brazilian cohort of multiple sclerosis | Felipe Menezes | ![]() |
![]() |
|||
444-P | Anticonvulsant & gabapentinoid pharmacotherapy in the multiple sclerosis prodrome: a population-based matched cohort study | Himali Bergeron-Vitez | ![]() |
![]() |
|||
447-P | Migraine in the multiple sclerosis prodrome. A prospective nationwide cohort study | Karine Eid | ![]() |
![]() |
|||
449-P | Changing age of multiple sclerosis onset from 1920 to 2022: a population-based study in Western Norway | Andrea Habbestad | ![]() |
![]() |
|||
450-P | The multiple sclerosis prodrome: Rates of physician visits were elevated in the 15 years before a first demyelinating event and differed by age and sex; an international matched cohort study. | Helen Tremlett | ![]() |
![]() |
|||
451-P | Chronic infections and malignancy screening in Mexican patients with multiple sclerosis before initiating disease modifying treatments. | lizeth zertuche | ![]() |
![]() |
|||
453-P | Clinical outcomes and treatment strategy of multiple sclerosis in China: Results from a real-world cross-sectional survey | Wenhao Wang | ![]() |
![]() |
|||
460-P | The Impact of Menopause on the Clinical Trajectory of Multiple Sclerosis | Francesca Bridge | ![]() |
![]() |
|||
462-P | Pregnancy and birth outcomes in MS women : comparison of the RESPONSE cohort to the general French population. | Elisabeth Maillart | ![]() |
![]() |
|||
463-P | Pregnancy reduces the risk of reaching irreversible EDSS 3 in women with multiple sclerosis, but theres a catch! | Vilija Jokubaitis | ![]() |
![]() |
|||
464-P | RESPONSE, a French cohort of pregnant women with MS and related disorders and their children until the age of 6. Protocol and baseline characteristics. | Sandra Vukusic | ![]() |
![]() |
|||
480-P | Relationship Between Socioeconomic Status and Depression in Patients with Multiple Sclerosis | Bryn Rubin | ![]() |
![]() |
|||
483-P | Clinical trial evidence of quality-of-life effects of disease modifying therapies for multiple sclerosis | Perrine Janiaud | ![]() |
![]() |
|||
485-P | MS Falls InsightTrack (MS-FIT): Design and Stakeholder Perspectives on a Closed-loop Falls Monitoring and Prevention Application for MS Clinical Practice | Valerie Block | ![]() |
![]() |
|||
486-P | Evaluating the patients experience after switching from natalizumab intravenous to subcutaneous administration. Analysis of a case series | Jose Meca Lallana | ![]() |
![]() |
|||
489-P | Risk of Relapse and Sustained Disability Progression in People with MS during the COVID-19 Pandemic | Ethan Huson | ![]() |
![]() |
|||
490-P | The socio-economic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study | Viktoria Papp | ![]() |
![]() |
|||
494-P | Comorbidity in the aging population with multiple sclerosis -- A nationwide cross-sectional study | Rolf Holm | ![]() |
![]() |
|||
496-P | Mediterranean Diet is Associated with Cognition in Multiple Sclerosis | Ilana Katz Sand | ![]() |
![]() |
|||
502-P | Axonal damage in early MS lesions and white matter correlate with neurofilament light chains in serum | Imke Metz | ![]() |
![]() |
|||
510-P | Pathogenic cerebrospinal fluid antibodies in oligoclonal band-negative primary progressive MS patients | Jamie Wong | ![]() |
![]() |
|||
519-P | A single cell multi-omics map of cell type specific mechanistic drivers of multiple sclerosis lesions | Maria Louise Elkjr | ![]() |
![]() |
|||
527-P | SARS-CoV-2 mRNA vaccination affects antibody and cellular immune responses after B-cell depletion therapies | Erin Longbrake | ![]() |
![]() |
|||
530-P | Cervical lymph nodes in patients with multiple sclerosis show an overrepresentation of memory B cells and a disturbed germinal center reaction | Sini Laakso | ![]() |
![]() |
|||
536-P | Spatial analysis of lymph nodes show increased follicular T cells in multiple sclerosis patients | Joona Sarkkinen | ![]() |
![]() |
|||
538-P | Expanded T lymphocyte clones in the cerebrospinal fluid of multiple sclerosis patients are specific for autologous Epstein-Barr virus infected B lymphocytes. | John Lindsey | ![]() |
![]() |
|||
548-P | In vitro infection of CNS-derived cells with Epstein-Barr virus using a B-cell transfer method | Roberto Alfonso | ![]() |
![]() |
|||
551-P | Inverse association between mediterranean diet and risk of multiple sclerosis | Lars Alfredsson | ![]() |
![]() |
|||
571-P | Increased white matter disconnectivity and inflammation in multiple sclerosis patients with paramagnetic rim lesions | Ceren Tozlu | ![]() |
![]() |
|||
574-P | Choroid plexus volume and slowly expanding lesions as inflammatory markers in relapsing multiple sclerosis. | Muhammad Raghib | ![]() |
![]() |
|||
575-P | Choroid plexus volume correlates with advanced MRI metrics in relapsing multiple sclerosis. | Muhammad Raghib | ![]() |
![]() |
|||
577-P | Inclusion of attention gates in a 3D CNN model improves the performance in new T2 lesion quantification | Sergi Valverde | ![]() |
![]() |
|||
579-P | Accumulation of iron-rim lesions correlates with change in cognition in early Multiple Sclerosis | Radu Tanasescu | ![]() |
![]() |
|||
584-P | Thalamus-derived Radiomic Features to Predict Symbol Digit Modalities Test Results in MS. | Korhan Buyukturkoglu | ![]() |
![]() |
|||
599-P | The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with acute optic neuritis. | Gorm Pihl-Jensen | ![]() |
![]() |
|||
600-P | Early neurofilament light chain levels are correlated with brain atrophy up to 4 years in dimethyl-fumarate treated patients with relapsing remitting multiple sclerosis | Tobias Sejbaek | ![]() |
![]() |
|||
613-P | Visible T2 thin cortical lines on MRI may reflect cortical damage in MS | Mohammad Aboulwafa | ![]() |
![]() |
|||
615-P | Neurodegeneration may occur without evidence of clinical or neuroinflammatory relapse in recently-diagnosed relapsing-remitting multiple sclerosis | Rozanna Meijboom | ![]() |
![]() |
|||
634-P | Plasma IgG Aggregates as Biomarkers for MS and for Diagnosing SPMS | Xiaoli Yu | ![]() |
![]() |
|||
635-P | Aberrant PD-1/PD-L1 expression in immune cell subsets and elevated soluble PD-L1 levels in mutiple sclerosis patients correlate with disease activity and disability | Thanos Tsaktanis | ![]() |
![]() |
|||
638-P | Trends, Features, and Utility of Testing Myelin Oligodendrocyte Glycoprotein Autoantibodies in CSF | Jodie Burton | ![]() |
![]() |
|||
641-P | Disease Activity Score and Disease Pathway Scores Measured Using the MSDA Test are Significantly Reduced Prior to the Week 48 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies | Melissa Karr | ![]() |
![]() |
|||
647-P | Large-scale cerebrospinal fluid proteomics of more than 4500 patients for biomarker discovery in multiple sclerosis | Christine Makarov | ![]() |
![]() |
|||
650-P | Immune cell surface markers reflect cognitive impairment in patients with MS, NMOSD and MOGAD | Kimberly Koerbel | ![]() |
![]() |
|||
660-P | Leveraging untargeted metabolomic profiling to discern biological processes dysregulated by recent relapse activity in multiple sclerosis | Farren Briggs | ![]() |
![]() |
|||
663-P | Stool glial fibrillary acidic protein is a biomarker of progressive multiple sclerosis and predicts disease worsening | Luke Schwerdtfeger | ![]() |
![]() |
|||
664-P | Retinal ganglion cell function in AQP4 and MOG Optic Neuritis | Katharina Messias | ![]() |
![]() |
|||
672-P | Improving Precision Medicine for Multiple Sclerosis with Uncertainty-Aware Causal Models | Jean-Pierre Falet | ![]() |
![]() |
|||
698-P | Effective depletion of CD20 lymphocytes after the first application of ofatumumab | Franz Felix Konen | ![]() |
![]() |
|||
700-P | Inhibiting CEMIP Activity in Demyelinating Lesions Promotes Functional Remyelination | Larry Sherman | ![]() |
![]() |
|||
703-P | The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in murine models of multiple sclerosis | Torbjrn Krkenes | ![]() |
![]() |
|||
708-P | Reduction in Absolute Lymphocyte Count in Patients Transitioning from Dimethyl Fumarate to Diroximel Fumarate. | Kyle Smoot | ![]() |
![]() |
|||
709-P | Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients With Relapsing Multiple Sclerosis | Amitha Singh Thakur | ![]() |
![]() |
|||
717-P | Prediction of gammaglobulin decrease during rituximab treatment in MS | Sandra Kallin | ![]() |
![]() |
|||
735-P | New methods to estimate the effect of disease modifying treatment on disability in multiple sclerosis in open observational cohort studies. | Melinda Magyari | ![]() |
![]() |
|||
736-P | Descriptive demographic and clinical characteristics for Alemtuzumab treated patients with MS vs. other disease modifying therapies treated patients with MS: Preliminary results of a feasibility analysis | Jian-Yu E | ![]() |
![]() |
|||
742-P | A Retrospective Analysis of Natalizumab First-line Versus Later-line Use in Multiple Sclerosis Treatment: Evidence from a US Claims Database Study | Mattia Gianinazzi | ![]() |
![]() |
|||
746-P | Characterizing up to 2 years of ofatumumab onboarding and utilization among real-world relapsing multiple sclerosis patients in Australia - the EAFToS Secondary Use of Data Study | Morag Nelson | ![]() |
![]() |
|||
755-P | Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis | Morag Nelson | ![]() |
![]() |
|||
760-P | Grey Matter Structural Changes and their Correlation with Tremor Severity in Multiple Sclerosis: A Case-Control Study | Ahmed Bayoumi | ![]() |
![]() |
|||
761-P | When does multiple sclerosis (MS) start? Findings from an international pediatric-onset MS population suggests higher than expected health care use from birth | Helen Tremlett | ![]() |
![]() |
|||
766-P | Increased Aerobic Glycolysis in Normal Appearing White Matter of Multiple Sclerosis Patients | Matthew Brier | ![]() |
![]() |
|||
768-P | Analysis of the Global Landscape of Multiple Sclerosis Research | Bruce Bebo | ![]() |
![]() |
|||
777-P | Increased Sleep Fragmentation and Circadian Irregularity are Associated with Cognitive Impairment in Multiple Sclerosis. | Jiyeon Son | ![]() |
![]() |
|||
780-P | The Role of Surveillance MRI in Paediatric-onset MOGAD and NMOSD: A Retrospective Cohort Study | Paridhi Shah | ![]() |
![]() |
|||
784-P | OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies | Erin Moskal | ![]() |
![]() |
11–13 October 2023 Milan
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|